Adaptive Biotechnologies Corp (ADPT) Stock Analysis
Verdict: WATCH (do not buy)
Exceptional revenue growth and diagnostic adoption are fighting a race against cash burn and high valuations after a 42% monthly rally.
Investment score: 58/100
Analysis as of
Is Adaptive Biotechnologies Corp stock worth reviewing? AI model thesis
Adaptive Biotechnologies (ADPT) is showing strong commercial execution in its MRD monitoring business, evidenced by a string of earnings beats. However, the 42% monthly price surge has pushed the valuation to a significant premium over peers (P/B 13.9x vs BIO 1.1x), and insiders are aggressively selling into the strength. The model recommends holding existing positions but awaiting a retracement for new entries.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 60/100 (weight 15%)
- Technical Momentum: 85/100 (weight 15%)
- Earnings Quality: 90/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 45/100 (weight 15%)
Adaptive Biotechnologies Corp opportunities and risks
What speaks for ADPT
- MRD Market Dominance
What speaks against ADPT
- Cash Runway and Dilution Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ADPT | n/a | 10.5x | n/a | 75.3% | -16.8% | -1.0% |
| RGEN | 152.1x | 10.2x | 45.9x | 50.3% | 6.7% | 1.3% |
| BIO | 45.8x | 2.9x | 18.0x | 51.9% | 6.5% | 4.7% |
| AVTR | n/a | 1.0x | 80.0x | 32.1% | -8.4% | 6.6% |
| SHC | 40.6x | 4.0x | 13.7x | 55.0% | 9.9% | 2.0% |
| TXG | n/a | 6.9x | 42.7x | 69.6% | -3.5% | 2.8% |
| Peer median | 40.6x | 4.0x | 42.7x | 51.9% | 6.5% | 2.8% |
Frequently asked questions about Adaptive Biotechnologies Corp (ADPT)
Is ADPT stock a good investment?
The cached TradeMates AI model rates Adaptive Biotechnologies Corp as WATCH (do not buy) with an investment score of 58/100. Adaptive Biotechnologies (ADPT) is showing strong commercial execution in its MRD monitoring business, evidenced by a string of earnings beats. However, the 42% monthly price surge has pushed the valuation to a significant premium over peers (P/B 13.9x vs BIO 1.1x), and insiders are aggressively selling into the strength. The model recommends holding existing positions but awaiting a retracement for new entries. This is algorithmic model output, not personal investment advice.
Is ADPT stock a buy?
The TradeMates model verdict for ADPT is WATCH (do not buy) with an investment score of 58/100. Treat this as a model signal to review, not a personal buy recommendation.